Varian Medical Systems Touts U.S., U.K. Wins for Brachytherapy Treatment, Profits Up 6 Pct in Q1

Palo Alto, Calif.-based medical device company Varian gets twin regulatory wins for its brachytherapy treatment for prostate cancer and posts stronger earnings in Q1. Varian Medical Systems (NYSE:VAR) is touting a pair of regulatory wins for the next generation of its Vitesse brachytherapy treatment for prostate cancer. Palo Alto, Calif.-based Varian received 510(k) clearance from the FDA and CE Mark approval in the European Union for the latest version of Vitesse, which company officials said reduces the complexity and number of steps involved in planning and completing brachytherapy treatment for prostate cancer. Brachytherapy involves delivering radiotherapy from inside the body by placing a tiny radioactive source directly into the tumor.